Left Atrial Appendage Closure (LAAC) Trials and Studies
ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
The ASAP study, a non-randomized feasibility study performed outside the US, was designed to assess the safety and efficacy of left atrial appendage closure (LAAC) in non-valvular atrial fibrillation (AF) patients ineligible for warfarin therapy.
Prospective Randomized Evaluation of the WATCHMAN™ LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy.
PROTECT AF Long Term
Long Term Results of PROTECT AF: The Mortality Effects of Left Atrial Appendage Closure Versus Warfarin For Stroke Prophylaxis in AF.
The WATCHMAN Left Atrial Appendage Closure (LAAC) Device for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) trial was a multicenter, prospective, randomized clinical trial designed to demonstrate that WATCHMAN is non-inferior to warfarin for the combined endpoint of stroke, systemic embolism and cardiovascular or unexplained death in patients with non-valvular AF who were eligible for warfarin therapy and had a CHADS2 score of ≥1